MyoKardia Inc. (NASDAQ:MYOK)’s share price was down 2.5% during mid-day trading on Wednesday . The stock traded as low as $17.02 and last traded at $17.22, with a volume of 60,693 shares traded. The stock had previously closed at $17.66.

MYOK has been the topic of several research analyst reports. Cowen and Company reissued a “buy” rating on shares of MyoKardia in a research note on Friday, May 13th. Credit Suisse Group AG reissued a “buy” rating on shares of MyoKardia in a research note on Tuesday. Zacks Investment Research raised MyoKardia from a “sell” rating to a “hold” rating in a research note on Tuesday, May 24th. Finally, Wedbush reissued an “outperform” rating and set a $22.00 price target on shares of MyoKardia in a research note on Thursday, May 12th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $21.33.

The company’s market cap is $471.05 million. The stock’s 50 day moving average price is $13.46 and its 200-day moving average price is $11.17.

MyoKardia (NASDAQ:MYOK) last issued its earnings results on Thursday, May 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.21. On average, equities research analysts forecast that MyoKardia Inc. will post ($1.56) earnings per share for the current year.

A hedge fund recently bought a new stake in MyoKardia stock. Casdin Capital LLC bought a new position in MyoKardia Inc. (NASDAQ:MYOK) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 403,872 shares of the company’s stock, valued at approximately $5,921,000. MyoKardia makes up about 5.2% of Casdin Capital LLC’s holdings, making the stock its 9th largest position. Casdin Capital LLC owned approximately 1.49% of MyoKardia as of its most recent SEC filing.

MyoKardia, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in the development of therapies for treating cardiovascular diseases. The Company focuses on developing and discovering therapies for hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.